Garrett Motion Inc., together with its subsidiaries, designs, manufactures, and sells turbocharging, air and fluid compression, and high-speed electric motor technologies for original equipment manufacturers and distributors in the United States, Europe, Asia, and internationally. The company offers cutting-edge technology for the mobility and industrial space, including light vehicles, commercial vehicles, and industrial applications. It also provides mechanical and electrical products for turbocharging and boosting internal combustion engines, as well as compressing air for fuel cell compressors, and compressing refrigerant for electric cooling compressors. It offers its products in the aftermarket through distributors. Garrett Motion Inc. was incorporated in 2018 and is based in Rolle, Switzerland.

Garrett Motion Inc

Cognition Therapeutics ( ($CGTX) ) has provided an announcement. On May 20, 2026, Cognition Therapeutics held a planned meeting with the U.S. Food ...

Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an update. Egetis Therapeutics will present new health economics research on healthcare resource d...

Egetis highlights MCT8 healthcare costs as Emcitate nears key U.S. review

Hugoton Royalty ( ($HGTXU) ) has released a notification of late filing. Hugoton Royalty Trust has filed a Form 12b-25 to notify investors of a del...

Hugoton Royalty Trust Warns of Delayed 10-Q Filing

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragt...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragtx Holdings (MGTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT...

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an update. Egetis Therapeutics will participate in a series of major international medical confere...

Egetis Targets Global Specialist Community With 2026 Conference Push

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX) and Insulet (PODD). TG Therapeutics (TGTX)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX) and Insulet (PODD)

An announcement from Egetis Therapeutics AB ( ($SE:EGTX) ) is now available. Egetis Therapeutics has secured a U.S. patent covering pharmaceutical ...

Egetis Gains Key U.S. Patent Protection for Emcitate in MCT8 Deficiency

There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on Aritzia (ATZAF) and Garrett Motion (GTX) with...

Analysts’ Top Consumer Cyclical Picks: Aritzia (ATZAF), Garrett Motion (GTX)

In a report released today, Ryan Brinkman from J.P. Morgan maintained a Buy rating on Garrett Motion, with a price target of $30.00. Brinkman cover...

J.P. Morgan Sticks to Their Buy Rating for Garrett Motion (GTX)

Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an announcement. Egetis Therapeutics will participate in the Pediatric Endocrine Society Annual ...

Egetis Uses Pediatric Endocrine Meeting to Build Momentum for Emcitate

An update from Egetis Therapeutics AB ( ($SE:EGTX) ) is now available. Egetis Therapeutics reported that the U.S. FDA has accepted and granted Prio...

Egetis Wins FDA Priority Review for Emcitate as EU Launch Gathers Pace

An update from Meiragtx Holdings ( ($MGTX) ) is now available. On April 20, 2026, MeiraGTx Holdings and affiliates completed the initial closing of...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GTX	$33.29	+0.21%	2.89M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GTX	$33.29	+0.2%	2.89M
3
4
5
6

GTX

GTX

Get Garrett Motion Inc Data in Excel

Get Garrett Motion Inc Data in Excel